CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+30.05%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$647M
AUM Growth
+$647M
(+0.35%)
Cap. Flow
-$87.5M
Cap. Flow
% of AUM
-13.52%
Top 10 Holdings %
Top 10 Hldgs %
48.48%
Holding
75
New
6
Increased
14
Reduced
49
Closed
4
Top Buys
| 1 |
Alkermes
ALKS
|
$15.2M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.5M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$13.3M |
| 4 |
Heron Therapeutics
HRTX
|
$8.29M |
| 5 |
PFNX
Pfenex Inc.
PFNX
|
$7.57M |
Top Sells
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$41.5M |
| 2 |
CELG
Celgene Corp
CELG
|
$33.6M |
| 3 |
Puma Biotechnology
PBYI
|
$12.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$11.2M |
| 5 |
Tempest Therapeutics
TPST
|
$9.87M |
Sector Composition
| 1 | Healthcare | 72.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARAV
51
DELISTED
Aravive, Inc. Common Stock
ARAV
| $3.12M | 0.48% |
28,333
-5,000
| -15% | -$551K |
|
|
NSTG
52
DELISTED
NanoString Technologies, Inc.
NSTG
| $2.8M | 0.43% |
275,000
-25,000
| -8% | -$255K |
|
|
DERM
53
DELISTED
Dermira, Inc.
DERM
| $2.61M | 0.4% |
170,000
-30,000
| -15% | -$461K |
|
|
IMDZ
54
DELISTED
Immune Design Corp.
IMDZ
| $2.51M | 0.39% |
119,000
-21,000
| -15% | -$443K |
|
|
KIN
55
DELISTED
Kindred Biosciences, Inc.
KIN
| $2.35M | 0.36% |
328,497
-21,503
| -6% | -$154K |
|
56
Neurogene
NGNE
$284M
| $2.3M | 0.36% |
13,995
-1,005
| -7% | -$165K |
|
|
AGRX
57
DELISTED
Agile Therapeutics, Inc
AGRX
| $1.69M | 0.26% |
91
+16
| +21% | +$297K |
|
58
Cellectar Biosciences
CLRB
$15.3M
| $1.65M | 0.25% |
18
| – | – |
|
|
BLCM
59
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $1.18M | 0.18% |
5,100
-900
| -15% | -$209K |
|
60
Akebia Therapeutics
AKBA
$827M
| $1.11M | 0.17% |
100,300
-17,700
| -15% | -$197K |
|
61
Ascendis Pharma
ASND
$12.1B
| $1.07M | 0.16% |
+61,500
| New | +$1.07M |
|
62
Veracyte
VCYT
$2.41B
| $984K | 0.15% |
135,190
+34,990
| +35% | +$255K |
|
63
Galectin Therapeutics
GALT
$288M
| $959K | 0.15% |
286,200
-25,800
| -8% | -$86.5K |
|
|
CLLS
64
Cellectis
CLLS
$260M
| $865K | 0.13% |
+25,000
| New | +$865K |
|
65
SCYNEXIS
SCYX
$35.2M
| $825K | 0.13% |
9,937
-63
| -0.6% | -$5.23K |
|
|
AGTC
66
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $520K | 0.08% |
26,010
-34,590
| -57% | -$692K |
|
67
PTC Therapeutics
PTCT
$4.41B
| $517K | 0.08% |
8,500
-1,500
| -15% | -$91.2K |
|
|
NVRO
68
DELISTED
NEVRO CORP.
NVRO
| $407K | 0.06% |
8,500
-1,500
| -15% | -$71.8K |
|
|
AKTX
69
Akari Therapeutics
AKTX
$21.4M
| $218K | 0.03% |
1,433
-67
| -4% | -$10.2K |
|
|
SAGE
70
DELISTED
Sage Therapeutics
SAGE
| $43K | 0.01% |
850
-150
| -15% | -$7.59K |
|
71
Adverum Biotechnologies
ADVM
$68.2M
| – | – |
-6,500
| Closed | -$3.51M |
|
|
ASPX
72
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| – | – |
-100,000
| Closed | -$5.25M |
|
|
CELG
73
DELISTED
Celgene Corp
CELG
| – | – |
-300,000
| Closed | -$33.6M |
|